This observation suggests that for anti-tumor immune responses, NAbs contribute to both innate and adaptive immunity, whereas DC1 mainly contributes to adaptive immunity, and in particular the activation of cytotoxic T cells. This evidence concerns the gene ZDHHC4 and neoplasm.